PD-(L)1 Oncology Pipeline

New drugs — Named, not approved in the US or China
Reached phase 3 — In an ongoing phase 3 with PD‑1 or PD‑L1; — of them only in a phase 2/3
In one trial only — Most are early, single-sponsor bets
Targets tested — About — drugs are chasing a novel target alone

Furthest phase reached

Each drug is counted once, at the furthest phase among its ongoing PD-1 or PD-L1 trials. Trials registered as phase 1/2 get their own bar; phase 2/3 trials count as phase 3. Select a bar to filter the table.

Phase 1 or other Phase 1/2 Phase 2 Phase 3 Colors in the charts below show the furthest phase each drug has reached with PD-1 or PD-L1.

What kind of drug

What it targets

Most crowded targets

Number of different new drugs aimed at each target. It leaves out undisclosed targets, new PD-1 and PD-L1 antibodies (the backbone the other drugs are added to), and personalized neoantigen vaccines and oncolytic viruses, which share an approach rather than a target.

Which cancers they're tested in

New drugs being tested in each cancer type, split by the furthest phase each drug has reached in that cancer. A drug can count under several cancers; trials open to many tumor types count as basket trials. Select a bar to filter the table.

Every new drug

—

Cancer types Example trial